InflaRx Investor Relations Material
Latest events
Investor Update
InflaRx
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from InflaRx N.V.
Access all reports
InflaRx N.V. is a clinical-stage biopharmaceutical company engaged in the discovery and development of drugs that inhibit the activation of the complement system, particularly targeting the C5a component, a potent inflammatory mediator. This focus addresses various autoimmune and other inflammatory diseases. The company's leading product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody with multiple clinical applications, including for diseases like hidradenitis suppurativa and cutaneous squamous cell carcinoma. The company is headquartered in Jena, Germany, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IFRX
Country
🇺🇸 United States